Latest News, Updates & Breaking Headlines
Pfizer is poised to acquire US-based biotechnology firm Metsera in a $10 billion deal, after winning a heated bidding battle against Danish drugmaker Novo Nordisk, which has now withdrawn from the race, AFP reported.Metsera, which specialises in obesity treatments, said in a statement that Pfizer’s improved offer of $86.25 per share had been unanimously approved…
Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo’s unsolicited offer challenges Pfizer’s earlier $7.3 billion deal, highlighting the immense value and competition in the booming weight-loss drug market. This corporate showdown could redefine the future of obesity treatment. Novo Nordisk, the Danish…
Pfizer has agreed to lower prescription drug costs for Medicaid and invest $70 billion in US manufacturing, President Donald Trump announced on Tuesday, in a move aimed at reducing healthcare costs.As of 1:26 PM (GMT-4), Pfizer shares were actively trading at $25.08, marking a sharp 5.14% gain, signaling strong investor interest and positive developments driving…
Pfizer is intensifying its entry into obesity treatments by acquiring development-stage drugmaker Metsera for $4.9 billion, the company announced Monday. The deal values each Metsera share at $47.50 in cash, a premium of more than 42% over Friday’s closing price, according to news agency AP report.Additional payments of $22.50 per share could be triggered depending…
